(Q61899631)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16649217%20AND%20SRC:MED&resulttype=core&format=json

30 August 2019

meta-analysis

0 references

title

Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16649217%20AND%20SRC:MED&resulttype=core&format=json

30 August 2019

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16649217%20AND%20SRC:MED&resulttype=core&format=json

30 August 2019

Diana Giannarelli

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16649217%20AND%20SRC:MED&resulttype=core&format=json

30 August 2019

author name string

Cecilia Nistico

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16649217%20AND%20SRC:MED&resulttype=core&format=json

30 August 2019

Federica Cuppone

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16649217%20AND%20SRC:MED&resulttype=core&format=json

30 August 2019

Paolo Carlini

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16649217%20AND%20SRC:MED&resulttype=core&format=json

30 August 2019

Mariangela Ciccarese

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16649217%20AND%20SRC:MED&resulttype=core&format=json

30 August 2019

Michele Milella

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16649217%20AND%20SRC:MED&resulttype=core&format=json

30 August 2019

Guido Natoli

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16649217%20AND%20SRC:MED&resulttype=core&format=json

30 August 2019

Edmondo Terzoli

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16649217%20AND%20SRC:MED&resulttype=core&format=json

30 August 2019

Francesco Cognetti

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16649217%20AND%20SRC:MED&resulttype=core&format=json

30 August 2019

language of work or name

English

0 references

publication date

1 June 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16649217%20AND%20SRC:MED&resulttype=core&format=json

30 August 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16649217%20AND%20SRC:MED&resulttype=core&format=json

30 August 2019

volume

106

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16649217%20AND%20SRC:MED&resulttype=core&format=json

30 August 2019

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16649217%20AND%20SRC:MED&resulttype=core&format=json

30 August 2019

page(s)

2337-2344

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16649217%20AND%20SRC:MED&resulttype=core&format=json

30 August 2019

cites work

Cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21886

7 January 2021

Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21886

7 January 2021

Taxanes with anthracyclines as first-line chemotherapy for metastatic breast carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21886

7 January 2021

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21886

7 January 2021

Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21886

7 January 2021

Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21886

7 January 2021

Adjuvant docetaxel for node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21886

7 January 2021

Meta-analyses of randomised clinical trials in oncology.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21886

7 January 2021

Interpreting Measures of Treatment Effect in Cancer Clinical Trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21886

7 January 2021

Overall survival is not a realistic end point for clinical trials of new drugs in advanced solid tumors: a critical assessment based on recently reported phase III trials in colorectal and breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21886

7 January 2021

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21886

7 January 2021

Effect of preoperative chemotherapy on the outcome of women with operable breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21886

7 January 2021

Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21886

7 January 2021

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21886

7 January 2021

Meta-analyses based on abstracted data: a step in the right direction, but only a first step.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21886

7 January 2021

Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21886

7 January 2021

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21886

7 January 2021

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21886

7 January 2021

Trastuzumab in the treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21886

7 January 2021

Identifiers

DOI

10.1002/CNCR.21886

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16649217%20AND%20SRC:MED&resulttype=core&format=json

30 August 2019

1 reference